With a 30 percent topline growth, Syngene, the research arm of Biocon, reported quarterly earnings for the first time since its listing. Speaking to CNBC-TV18, Manoj Nerurkar, COO, of the company, says he expects the momentum to continue for the rest of the year.On currency movements, he says hedging all the long-term contracts protects the company from the rupee-dollar volatility.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
